how big is Phaarmasia?

As of Jun 06, Phaarmasia Ltd has a market capitalization of 19.00 Cr, with recent net sales of 24.37 Cr and a net profit of -1.59 Cr over the last four quarters. The balance sheet shows shareholder's funds of 10.30 Cr and total assets of 31.37 Cr.

As of Jun 06, Phaarmasia Ltd has a market capitalization of 19.00 Cr, categorizing it as a Micro Cap company.<BR><BR>As of Jun 06, the company's recent quarterly performance shows a sum of Net Sales for the latest 4 quarters at 24.37 Cr and a sum of Net Profit at -1.59 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Balance Sheet Snapshot indicates that this is Standalone data for the latest annual period, with Shareholder's Funds reported at 10.30 Cr and Total Assets at 31.37 Cr.

What does Phaarmasia do?

Phaarmasia Ltd manufactures and markets oral contraceptive and iron tablets, classified as a Micro Cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 5 Cr and a net loss of 1 Cr, with a market cap of Rs 19 Cr.

Overview: <BR>Phaarmasia Ltd is engaged in the manufacturing and marketing of oral contraceptive tablets and iron tablets, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1981, Phaarmasia Ltd is a part of Maneesh Pharmaceutical Limited. The company established its second unit in 1993-94. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 19 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: -18.19% <BR>Price to Book: 2.15<BR><BR>Contact Details: <BR>Address: 16 Phase III, I D A Jeedimetla Hyderabad Telangana : 500055 <BR>Tel: 91-40-23095002/23095690 <BR>Email: phaarmasia@yahoo.com / phaarmasia@gma <BR>Website: http://www.phaarmasia.com

Has Phaarmasia declared dividend?

No Dividend History Available

Who are the peers of the Phaarmasia?

Phaarmasia's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Desh Rakshak, Parmax Pharma, Venmax Drugs, and Saroja Pharma. Phaarmasia has below average management risk, growth, and capital structure compared to its peers, with a 1-year return of -24.74%, significantly lower than Desh Rakshak's 422.50%.

Peers: The peers of Phaarmasia are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Desh Rakshak, Parmax Pharma, Venmax Drugs, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Saroja Pharma In, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Phaarmasia, Desh Rakshak, and Parmax Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted for Torrent Pharma, and Below Average capital structure is observed at Phaarmasia, Desh Rakshak, Parmax Pharma, and Saroja Pharma In.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while Phaarmasia has the lowest at -24.74%. This indicates that Phaarmasia's performance is significantly worse than that of Desh Rakshak. Additionally, the six-month return is negative for Phaarmasia, Cipla, Torrent Pharma, and Dr Reddy's Labs.

What is the technical trend for Phaarmasia?

As of June 5, 2025, Phaarmasia's trend is mildly bearish, with mixed signals from indicators like MACD and Bollinger Bands, suggesting a cautious approach due to prevailing bearish sentiment in the longer term.

As of 5 June 2025, the technical trend for Phaarmasia has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD on a weekly basis is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, suggesting a potential continuation of the downward trend. Moving averages on a daily basis are bearish, reinforcing the negative outlook. The KST shows a mildly bullish signal weekly but is bearish monthly, while Dow Theory indicates a mildly bearish trend weekly and mildly bullish monthly. Overall, the mixed signals across different indicators suggest a cautious approach, with the bearish sentiment prevailing in the longer term.

Who are in the management team of Phaarmasia?

As of March 2023, the management team of Phaarmasia includes Vinay Ramakant Sapte (Director), Maneesh R Sapte (Non Executive Director), Y N Bhaskara Rao (Whole-time Director), Rashmi V Sapte (Director), Pravin M. Hegde (Independent Director), Ajit G Jamkhandikar (Independent Director), and Urvashi Bhatia (Company Secretary & Compliance Officer). Each member plays a key role in the company's governance and operations.

As of March 2023, the management team of Phaarmasia includes the following members:<BR><BR>1. Vinay Ramakant Sapte - Director<BR>2. Maneesh R Sapte - Non Executive Director<BR>3. Y N Bhaskara Rao - Whole-time Director<BR>4. Rashmi V Sapte - Director<BR>5. Pravin M. Hegde - Independent Director<BR>6. Ajit G Jamkhandikar - Independent Director<BR>7. Urvashi Bhatia - Company Secretary & Compliance Officer<BR><BR>Each member holds a specific designation within the company, contributing to its governance and operational oversight.

Who are the top shareholders of the Phaarmasia?

The top shareholder of Phaarmasia is Maneesh Pharmaceuticals Limited, with a 44.22% stake. Individual investors, led by Madhavi Pradeep Save at 1.73%, collectively own 26.18%, while there are no mutual funds or foreign institutional investors involved.

The top shareholders of Phaarmasia include Maneesh Pharmaceuticals Limited, which holds the largest stake at 44.22%. The majority of the company's shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Madhavi Pradeep Save is the highest individual investor, holding 1.73%. Additionally, individual investors collectively own 26.18% of the company. There are currently no mutual funds or foreign institutional investors holding shares in Phaarmasia.

When is the next results date for Phaarmasia?

The next results date for Phaarmasia is 11 August 2025.

The next results date for Phaarmasia is scheduled for 11 August 2025.

Are Phaarmasia latest results good or bad?

Phaarmasia's latest results show a mixed performance: net sales and profit after tax have declined significantly year-on-year, but there was a notable quarter-on-quarter growth in net sales and profit for the latest quarter, indicating some positive trends despite long-term challenges.

Phaarmasia's latest results indicate a mixed performance overall. On one hand, the company has experienced a significant decline in net sales and profit after tax, with net sales down 32.71% year-on-year and a reported loss of Rs -0.26 crore for the period. This negative trend suggests challenges in maintaining revenue and profitability.<BR><BR>However, there are some positive signs in the quarterly results. For the quarter ending June 2025, Phaarmasia reported a quarter-on-quarter growth in net sales of 26.52% and a substantial increase in standalone net profit of 150.94%. Additionally, the Debtors Turnover Ratio has improved to 7.84 times, indicating better efficiency in collecting debts.<BR><BR>In summary, while the long-term outlook appears challenging due to declining sales and profits, the recent quarterly performance shows some encouraging growth trends.

How has been the historical performance of Phaarmasia?

Phaarmasia's historical performance has shown a decline in net sales and profitability, with net sales dropping from 30.59 Cr in March 2024 to 24.37 Cr in March 2025, and operating profit worsening from -0.17 Cr to -1.26 Cr during the same period. Total assets and liabilities also decreased, leading to a reduced book value per share from 8.87 to 6.58.

Answer:<BR>The historical performance of Phaarmasia shows a fluctuating trend in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Phaarmasia's net sales peaked at 30.59 Cr in March 2024 but fell to 24.37 Cr by March 2025. The total operating income followed a similar pattern, decreasing from 30.59 Cr in March 2024 to 24.37 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 31.42 Cr in March 2024 to 26.38 Cr in March 2025, yet the operating profit (PBDIT) remained negative, worsening from -0.17 Cr in March 2024 to -1.26 Cr in March 2025. Profit before tax also declined, moving from -0.55 Cr in March 2024 to -1.60 Cr in March 2025, while profit after tax showed a similar trend, dropping from -0.52 Cr to -1.59 Cr in the same period. The company's total assets decreased from 31.37 Cr in March 2024 to 21.47 Cr in March 2025, with total liabilities also declining from 31.37 Cr to 21.47 Cr. The book value per share adjusted down from 8.87 in March 2024 to 6.58 in March 2025, reflecting the overall downward trend in financial performance.

Should I buy, sell or hold Phaarmasia?

Is Phaarmasia overvalued or undervalued?

As of November 21, 2025, Phaarmasia is considered overvalued with a high PE ratio of 42.96 and lagging stock performance, compared to peers like Sun Pharma and Cipla, which have lower valuation metrics.

As of 21 November 2025, Phaarmasia's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 42.96, an EV to EBIT ratio of 33.08, and a Price to Book Value of 3.12. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla is valued attractively with a PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these metrics, Phaarmasia appears overvalued in the current market environment. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of only 1.20% compared to the Sensex's 9.08%, further reinforcing the assessment of overvaluation.

Which are the latest news on Phaarmasia?

Why is Phaarmasia falling/rising?

As of 14-Dec, Phaarmasia Ltd's stock price is rising to Rs. 92.57, supported by a new 52-week high and impressive returns of 180.52% over the past 21 days. Despite a decline in investor participation, the stock continues to show strong performance across various time frames.

As of 14-Dec, Phaarmasia Ltd's stock price is rising, currently at Rs. 92.57, reflecting an increase of Rs. 1.81 or 1.99%. This upward movement is supported by several key factors. The stock has achieved a new 52-week high today, indicating strong performance. Over the past 21 days, it has consistently gained, resulting in an impressive 180.52% return during this period. Additionally, Phaarmasia has outperformed the sector by 1.94% today, further highlighting its positive momentum.<BR><BR>In terms of longer-term performance, Phaarmasia has shown remarkable returns across various time frames, including a 172.42% increase over the past month and a 90.87% rise year-to-date. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 68.45% against the 5-day average. Despite this decrease in participation, the overall liquidity remains sufficient for trading. Overall, the combination of strong recent performance, significant returns over multiple periods, and the achievement of a new high contributes to the rising stock price of Phaarmasia Ltd.